Suppr超能文献

玻璃体切除术中结膜下注射0.1%肾上腺素与安慰剂用于维持瞳孔散大的随机对照试验

Subconjunctival 0.1% epinephrine versus placebo in maintenance of mydriasis during vitrectomy: a randomized controlled trial.

作者信息

de Araújo Rafael B, Azevedo Breno M S, Andrade Thais S, Abalem Maria F, Monteiro Mário L R, Carricondo Pedro C

机构信息

1Division of Ophthalmology, Hospital Universitário Onofre Lopes, Universidade Federal do Rio Grande do Norte, Rua Mipibu, 741 apt 1402A, Natal, RN 59014-480 Brazil.

2Division of Ophthalmology, Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Rua Dr. Ovídio Pires de Campos, 225, 05403-010 São Paulo, SP Brazil.

出版信息

Int J Retina Vitreous. 2018 Oct 17;4:38. doi: 10.1186/s40942-018-0142-y. eCollection 2018.

Abstract

BACKGROUND

Pupil dilation and mydriasis maintenance throughout vitreoretinal surgeries are important to allow satisfactory fundus visualization and reduce risk of complications. The purpose of this study is to evaluate the role of subconjunctival epinephrine 0.1% injection in mydriasis maintenance during vitrectomy.

METHODS

Ninety-nine consecutive patients undergoing vitrectomy were enrolled. All subjects were preoperatively dilated with tropicamide 1%. Each patient was randomly allocated either in the epinephrine or placebo group. In epinephrine group, patients were submitted to a 0.2 cc subconjunctival injection of a 0.1% epinephrine solution just before first incisions. In placebo group, the same procedure was performed with 0.2 cc of saline 0.9%. Horizontal pupil diameter was measured with calipers before and in the end of the procedure.

RESULTS

Patients in the epinephrine group showed a significantly larger mean pupil diameter in the end of the surgery compared to placebo. There was a significant increase of mean pupil diameter from the beginning to the end of the surgery in such patients. Blood pressure was significantly higher in the epinephrine group than in placebo group. No other adverse effects were noted.

CONCLUSION

Subconjunctival epinephrine is effective for maintaining and increasing pupil size during vitrectomy, compared to placebo. Caution should be taken regarding intraoperative blood pressure levels.

TRIAL REGISTRATION

RBR; RBR-3qzhvg; Registered 8 May 2018-Retrospectively registered, http://www.ensaiosclinicos.gov.br/rg/RBR-3qzhvg/.

摘要

背景

在玻璃体视网膜手术中,瞳孔扩张及维持散大对于获得满意的眼底视野及降低并发症风险至关重要。本研究旨在评估结膜下注射0.1%肾上腺素在玻璃体切除术中维持瞳孔散大的作用。

方法

纳入99例连续接受玻璃体切除术的患者。所有受试者术前均用1%托吡卡胺散瞳。每位患者随机分为肾上腺素组或安慰剂组。肾上腺素组患者在首次切口前接受结膜下注射0.2cc 0.1%肾上腺素溶液。安慰剂组采用相同操作,注射0.2cc 0.9%生理盐水。手术开始前及结束时用卡尺测量水平瞳孔直径。

结果

与安慰剂组相比,肾上腺素组患者在手术结束时平均瞳孔直径明显更大。该组患者手术开始至结束时平均瞳孔直径显著增加。肾上腺素组血压明显高于安慰剂组。未观察到其他不良反应。

结论

与安慰剂相比,结膜下注射肾上腺素在玻璃体切除术中对维持和增大瞳孔大小有效。术中应注意血压水平。

试验注册

RBR;RBR-3qzhvg;2018年5月8日注册——回顾性注册,http://www.ensaiosclinicos.gov.br/rg/RBR-3qzhvg/

相似文献

本文引用的文献

1
Intracameral Use of Nepafenac: Safety and Efficacy Study.
Curr Eye Res. 2018 May;43(5):630-638. doi: 10.1080/02713683.2017.1408129. Epub 2017 Dec 4.
10
Obtained mydriasis in long-term type 2 diabetic patients.在长期 2 型糖尿病患者中出现散瞳。
J Ocul Pharmacol Ther. 2011 Dec;27(6):599-602. doi: 10.1089/jop.2011.0090. Epub 2011 Aug 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验